Survival within each cytogenetic response category by cytogenetic response achieved at 12 months with imatinib mesylate and interferon-α
. | Imatinib mesylate . | . | . | IFN-α . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | Survival . | . | . | Survival . | . | . | ||||
| Cytogenetic response at 12 mo . | No. . | At 3 y, % . | Median, mo. . | No. . | At 3 y, % . | Median, mo. . | P . | ||||
| Complete | 210 | 99 | NR | 70 | 97 | NR | .40 | ||||
| Partial | 21 | 100 | NR | 64 | 94 | NR | .54 | ||||
| Minor | 6 | 75 | NR | 132 | 90 | 118 | .97 | ||||
| None | 11 | 88 | 56 | 194 | 84 | 95 | .94 | ||||
. | Imatinib mesylate . | . | . | IFN-α . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | Survival . | . | . | Survival . | . | . | ||||
| Cytogenetic response at 12 mo . | No. . | At 3 y, % . | Median, mo. . | No. . | At 3 y, % . | Median, mo. . | P . | ||||
| Complete | 210 | 99 | NR | 70 | 97 | NR | .40 | ||||
| Partial | 21 | 100 | NR | 64 | 94 | NR | .54 | ||||
| Minor | 6 | 75 | NR | 132 | 90 | 118 | .97 | ||||
| None | 11 | 88 | 56 | 194 | 84 | 95 | .94 | ||||
NR indicates not reached. Analysis excluded patients who died before 12 months or who were taken off therapy prior to the 12-month analysis.